March 7, 2014 by Brad Perriello
Biomet is planning to put itself back on the public market after a 7-year run under private equity ownership, the orthopedics giant said today.
Semler Scientific is lowering its IPO price, now seeking $10 million instead of the previous $15 million it desired.
Portland, Ore.-based Semler specializes in medical risk-assessment. The company’s flagship product is the FloChec, which tracks blood flow in lower and upper extremities. The device is cleared by the FDA, according to the company’s website.